User
Write something
🐎 DARK HORSE — THE FINAL CHAPTER
Peptides: Out of the Shadows After considerable thought, I've made the decision to permanently close Dark Horse — Peptides: Out of the Shadows. Our anticipated closure is potentially by November 30, 2026, once all outstanding orders have been received and shipped. No additional group buys or new orders will be accepted. WHY I'VE MADE THIS DECISION When I created Dark Horse, my vision was to build something more than another peptide buying group. I wanted a community of curious, engaged individuals who were interested in exploring the science, challenging assumptions, exchanging knowledge, and contributing to meaningful discussions. Over the past year, I've invested countless hours researching complicated subjects, preparing educational deep dives, investigating independent laboratory testing, evaluating emerging compounds, and organizing group buys. Unfortunately, the level of member participation and engagement never developed into what I had hoped or envisioned. Despite the amount of information shared and the opportunities provided, meaningful participation has consistently come from a very small percentage of our membership. To those individuals — and you know who you are — I want to extend my sincere appreciation and thanks for your contributions, involvement, and support in helping Dark Horse develop over this past year. Your participation did not go unnoticed, and I am genuinely grateful. A community, at least in my view, should be more than a place where information is posted and passively consumed. It should be a place where members exchange ideas, ask questions, challenge findings, and contribute to the collective knowledge. That simply hasn't happened to the degree I had hoped. I certainly don't expect everyone to participate in every discussion. But maintaining a research-focused community requires more than the efforts of one individual. At this point, I've concluded that continuing to invest substantial time and energy into something that hasn't developed the collaborative environment I envisioned no longer makes sense.
Semax, Selank & Adamax: When Science Ends and Experimentation Begins
If you spend enough time around the peptide space, you start to notice a pretty sharp line between two completely different worlds: legit, old-school Soviet institutional medicine, and modern Western grey-market chemistry. Semax and Selank belong to that first world. Back in the early 1980s, researchers at the Institute of Molecular Genetics in Moscow weren't trying to help tech workers cram for a deadline. They were trying to build actual hospital drugs for stroke recovery, optic nerve damage, and severe clinical anxiety. The big hurdle with natural hormone fragments—like the ACTH fragment Semax is built on, or the tuftsin peptide behind Selank—is that enzymes in your blood chew them up in minutes. Those Russian scientists figured out that if you tack a specific three-amino-acid tail (Pro-Gly-Pro) onto the end, the molecule survives long enough to actually reach the brain through a nasal spray. They ran the animal models, ran the human trials, and got both compounds approved as actual prescription meds in Russia. Before we get into how the grey market got its hands on these molecules, it’s worth taking a brief detour to look at why "approved in Russia" doesn't translate to the U.S.—because the two systems collect human data and fund drug development in completely different ways. In the U.S. system, a drug sits inside a tightly controlled, FDA-regulated clinical process with strictly defined procedures. Moving through those phases takes several years and massive financial investment just to bring a single compound to market. In the Eastern European and Russian model, once baseline safety was established, compounds like Semax were deployed directly into hospital neurology wards and outpatient clinics. Researchers collected real-time data across hundreds of participants over years and decades of continuous clinical use. Instead of relying solely on a rigid, corporate-funded trial pipeline, they built a massive body of longitudinal, real-world clinical evidence. This is where bright-line patent rules enter the picture and essentially lock the door for pharmaceutical companies. Under U.S. intellectual property law, there is a hard bright line separating a patentable "invention" from a "product of nature" or an already-published public discovery. You cannot patent a naturally occurring amino acid sequence, and you cannot claim exclusive ownership over a foundational peptide structure that has been sitting in public scientific journals for decades. To cross that bright-line threshold and secure a patent, a company has to chemically engineer a markedly different synthetic molecule from scratch.
Semax, Selank & Adamax: When Science Ends and Experimentation Begins
🐎 DARK HORSE — TWO COMMUNITIES I HIGHLY RECOMMEND
As Dark Horse prepares to close, I'd like to recommend two outstanding Skool communities for members looking for a new home. I've personally belonged to both groups since their early days, when they were considerably smaller and membership was free. Both have grown substantially and are now paid-membership communities accepting new members through referrals. What sets these communities apart is their active member participation, excellent ownership, and extensive selection of products and purchasing opportunities. Both have developed strong memberships where people interact, share experiences, exchange information, and help one another navigate the peptide marketplace. I've watched both communities grow and have tremendous respect for their owners and what they've built. 🐎 The Peptide Collective https://www.skool.com/the-peptide-collective/about?ref=648bc4ef92e7405fa3121db3acfb8e47 🐎 Divine Bougie https://www.skool.com/divinebougie4/about?ref=648bc4ef92e7405fa3121db3acfb8e47 If you're looking for an active community with a broad range of product offerings and engaged members, I wholeheartedly recommend exploring both. These are personal recommendations based on my own membership and experience. Thank you again for being part of Dark Horse — Peptides: Out of the Shadows.
3
0
🐴 DARK HORSE | Taking My DIY Peptide Skincare to the Next Level — MICRONEEDLING!
For well over a year, I've been experimenting with my own DIY skincare formulations, including peptide serums and moisturizers. My experiments have included GHK-Cu (Copper Peptide), Matrixyl, Argireline, SNAP-8, and SYN-AKE, all with different potential benefits for skin appearance, collagen support, fine lines, and wrinkles. But today was a first for me! I decided to take my skincare experimentation a step further and try facial microneedling. 🔬 Why Microneedling? Microneedling creates thousands of tiny, controlled punctures in the skin, triggering the body's natural repair process. My research is to see if that process may help: 🔹 Stimulate collagen regeneration — Encouraging new collagen production and remodeling. 🔹 Promote skin renewal — Activating the skin's natural repair response. 🔹 Improve skin texture — Helping create a smoother, more even appearance. 🔹 Reduce fine lines and wrinkles — Through gradual collagen remodeling. 🔹 Improve skin firmness and elasticity — Supporting healthier-looking, more resilient skin. 🧪 My DIY Peptide Serum For today's experiment, I used a formulation I prepared myself. Base: 2 oz Cosmedica Hyaluronic Acid Serum 🔹 GHK-Cu: 600 mg (approximately 1.0%) 🔹 SYN-AKE: 100 mg (approximately 0.17%) 🔹 SNAP-8: 100 mg (approximately 0.17%) Why these three peptides? GHK-Cu (Copper Peptide) — Studied for its potential to support collagen production, skin repair, and tissue remodeling. SYN-AKE — A cosmetic peptide designed to soften the appearance of expression lines and wrinkles. SNAP-8 — A cosmetic peptide developed to target expression wrinkles, particularly around the forehead and eyes. My thinking is to explore whether combining the collagen-stimulating effects of microneedling with these cosmetic peptides produces noticeable improvements. Whether this combination offers any additional benefit over microneedling alone remains to be seen. ⚙️ My First Microneedling Session Device: Dr. Pen M8S Cartridge: 24 pins Needle depths: 🔹 0.25 mm — Around the eyes and forehead
RETATRUTIDE, ELI LILLY & OUR BRIGHT LINE RULE
If you've followed Dark Horse for any length of time, you know we have a Bright Line Rule: We separate what something IS scientifically from how regulators CLASSIFY it legally. Those two things are not always the same. And there may not be a better current example than retatrutide. Eli Lilly and the FDA are currently fighting in federal court over a deceptively simple question: Is retatrutide legally a “biological product”? At the center of the dispute is something we've discussed many times before—amino-acid length and the regulatory line between peptides and proteins. Under FDA's regulatory definition, a protein is generally an alpha-amino-acid polymer with a specific defined sequence that is greater than 40 amino acids in size. Retatrutide contains 41 amino-acid residues in its overall structure. So Lilly's position essentially starts here: 41 > 40. Therefore, Lilly argues retatrutide qualifies as a protein and consequently should be regulated as a biological product. FDA disagrees. FDA's position is that the definition turns specifically on alpha amino acids. Because of the modified/non-alpha component within retatrutide, FDA concluded that retatrutide does not contain more than 40 alpha amino acids and therefore does not meet FDA's regulatory definition of a protein. That disagreement eventually landed in federal court. And this is where the story gets more interesting. The District Court agreed with FDA on one important point: Retatrutide does not qualify as a “protein” under FDA's interpretation of the regulatory definition. But Lilly didn't completely lose. The court separately found that FDA had not adequately explained its determination that retatrutide was not “analogous to a protein.” That portion of FDA's decision was vacated and sent back to the agency for reconsideration. Lilly appealed. And today, September 24, 2026, the Seventh Circuit Court of Appeals is scheduled to hear oral arguments in the case. There is another legal issue involved as well. Lilly argues that after the District Court sent the matter back to FDA, the agency failed to act within the statutory time period—and that the consequence should be granting Lilly the biological-product designation it originally requested.
RETATRUTIDE, ELI LILLY & OUR BRIGHT LINE RULE
1-30 of 320
powered by
Peptides: Out of the Shadows
skool.com/monument-method-2583
Your Body. Your Code.
The science is out. The code is yours to write.
A place to share real peptide experiences and see what’s actually working.
Build your own community
Bring people together around your passion and get paid.
Powered by